Skip to main content

Advertisement

Figure 1 | Arthritis Research & Therapy

Figure 1

From: The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients

Figure 1

Association between clinical activity (Ankylosing Spondylitis Disease Activity Score) and immunogenicity. Ankylosing Spondylitis Disease Activity Score (ASDAS; mean ± standard deviation) measured at baseline (first and second anti-TNF drugs) and at 6 months after switching to a second anti-TNF drug in patients who did or did not develop anti-drug antibodies (ADA) against the first anti-TNF drug.

Back to article page